NETRF Announces grant funding for neuroendocrine cancer research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Neuroendocrine Tumor Research Foundation announced its latest Request for Applications and invites innovative research applications in neuroendocrine tumors that can bring the field closer to more effective therapies.

This uncommon cancer occurring in hormone-producing cells is often overlooked for research funding. NETRF serves as the major private funder of NET cancer research.

To ensure that high-quality, meaningful research proposals are selected, NETRF uses a rigorous peer review process, which includes external expert reviewers and a Board of Scientific Advisors.

Interested applicants must submit a letter of intent by June 13. From that pool, exceptional investigators with the most promising and transformative ideas will be invited to submit full proposals. Grant awards will be announced in December 2018.

Last year NETRF invested heavily in a targeted form of radiation called peptide receptor radionuclide therapy.

Since 2005, NETRF has funded $20 million in scientific research grants to expand the molecular understanding of NETs and help drive personalized treatment options for patients. NET research projects have been funded in the U.S., Canada, United Kingdom, Switzerland, Australia, and the Netherlands.

Table of Contents

YOU MAY BE INTERESTED IN

The day before health economist Jay Bhattacharya stepped into his new role as NIH director, he sent a document to his employees outlining his top five priorities for the department, which included “reproducibility” and “transparency,” two themes he discussed at his confirmation hearings (The Cancer Letter, March 7, 2025).

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login